Both measures topped the average estimate of analysts surveyed by Zacks Investment Research for Illumina earnings of $1.59 per share on $944 million in sales.That guidance doesn't include any potential impact from Illumina and Pacific Biosciences' (PACB) decision to terminate their agreed-upon merger.